Viridian Therapeutics, Inc. (VRDN)
28.75
-1.32
(-4.39%)
USD |
NASDAQ |
Feb 12, 16:00
28.19
-0.56
(-1.95%)
After-Hours: 20:00
Viridian Therapeutics Cash from Investing (Quarterly) : 126.08M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | 0.00 |
| ADMA Biologics, Inc. | -14.37M |
| Avantor, Inc. | -39.70M |
| Immunovant, Inc. | 0.00 |
| Plus Therapeutics, Inc. | 1.297M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -84.61M |
| Cash from Financing (Quarterly) | 10.86M |
| Free Cash Flow | -326.34M |
| Free Cash Flow Per Share (Quarterly) | -1.036 |
| Free Cash Flow to Equity (Quarterly) | -85.52M |
| Free Cash Flow to Firm (Quarterly) | -84.18M |
| Free Cash Flow Yield | -13.98% |